Classical clinical trial design in testicular cancer: Time to move on

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages 769-771

  Nichols, Craig R ^a   Roth, Bruce ^b   Kollmannsberger, Christian ^c  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; EDITORIAL; GERM CELL TUMOR; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TESTIS CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL;

EID: 84858821746     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.2503     Document Type: Editorial

References (11)

1. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
2. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435, 1987
3. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers-International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
4. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989 (Pubitemid 19075021)
5. Motzer RJ, Nichols CJ, Margolin KA, et al: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247-256, 2007 (Pubitemid 350003012)
6. de Wit R, Skoneczna I, Daugaard G, et al: Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: Intergroup Study EORTC 30983. J Clin Oncol 30:792-799, 2012
7. Kollmannsberger C, Daneshmand S, So A, et al: Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 28:537-542, 2010
8. Olofsson SE, Tandstad T, Jerkeman M, et al: Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: A report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 29:2032-2039, 2011
9. Kris MG, Meropol NJ, Winer EP (eds): Accelerating progress against cancer: ASCO's blueprint for transforming clinical and translational cancer research. http://www.asco.org/ASCOv2/Department%20Content/Cancer% 20Policy%20and%20Clinical%20Affairs/Downloads/Blueprint.pdf
10. Abernethy AP, Etheredge LM, Ganz PA, et al: Rapid-learning system for cancer care. J Clin Oncol 28:4268-4274, 2010
11. Frankovich J, Longhurst CA, Sutherland SM: Evidence-based medicine in the EMR era. N Engl J Med 365:1758-1759, 2011